Established in 2011, SnackSafely.com provides straightforward, actionable information to help improve the lives of the estimated 32 million people in the US suffering with food allergies.

We strive to eliminate anaphylaxis by leveraging our on-line properties to educate, advocate, and connect the allergic community with products and services that help toward achieving this goal.

Our blog covers topics of interest to the food allergy community including news reports; ongoing research, clinical studies, trials and progress toward treatment and cure; general advocacy; and advice regarding food safety and school policies.

Please see our Terms of Service and Privacy Policy.

Tag: Aimmune Therapeutics

From FDA Landmark to Market Exit: The Complex Journey of Palforzia

Aravax’s Phase 2 Study Now Enrolling Children with Peanut Allergy

Epinephrine-Treated Reactions for Palforzia are Half as Common vs Other Peanut...

Study Determines What Patients Prefer for Maintenance After Completing OIT with...

Positive Results from Phase 3 Study of PALFORZIA® in Peanut-Allergic Children...

You’re Invited: Patient and Advocacy Educational Presentation by Aimmune Therapeutics

Nestlé Acquires Aimmune, Partners with Enterome to Develop Food Allergy and...

This Holiday Season, See the Potential Impact that Peanut Allergy Treatment...

Notebooks, check. Backpack, check. Peanut allergy treatment, check.

Study: More Than 80% of Patients Could Tolerate 2000mg of Peanuts...

Follow Us

Your School On Our Map

Put Your School on the Map